- Open Access
Osteoprotegerin (OPG) activates integrin, focal adhesion kinase (FAK), and Akt signaling in ovarian cancer cells to attenuate TRAIL-induced apoptosis
© Lane et al.; licensee BioMed Central Ltd. 2013
- Received: 11 September 2013
- Accepted: 20 November 2013
- Published: 23 November 2013
Resistance to apoptosis is a major problem in ovarian cancer (OC) and correlates with poor prognosis. Osteoprotegerin (OPG) is a soluble secreted factor that acts as a decoy receptor for receptor activator of NF-κB ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). OPG has been reported to attenuate TRAIL-induced apoptosis in a variety of cancer cells, including OC cells. OPG-mediated protection against TRAIL has been attributed to its decoy receptor function. However, OPG activates integrin/focal adhesion kinase (FAK) signaling in endothelial cells. In OC cells, activation of integrin/FAK signaling inhibits TRAIL-induced apoptosis. Based on these observations, we hypothesized that OPG could attenuate TRAIL-induced apoptosis in OC cells through integrin/FAK signaling.
In vitro experiments including immunoblots, colony formation assays, and apoptosis measurements were used to assess the effect of OPG on TRAIL-induced apoptosis.
Exogenous OPG protected from TRAIL-induced apoptosis in a TRAIL binding-independent manner and OPG protection was αvβ3 and αvβ5 integrin/FAK signaling-dependent. Moreover, OPG-mediated activation of integrin/FAK signaling resulted in the activation of Akt. Inhibition of both integrin/FAK and Akt signaling significantly inhibited OPG-mediated attenuation of TRAIL-induced apoptosis. Although OPG also stimulated ERK1/2 phosphorylation, inhibition of ERK1/2 signaling did not significantly altered OPG protection.
Our studies provide evidence, for the first time, that OPG can attenuate TRAIL-induced apoptosis in a TRAIL binding-independent manner through the activation of integrin/FAK/Akt signaling in OC cells.
- Osteoprotegerin (OPG)
- Ovarian carcinoma
Osteoprotogerin (OPG) is a secreted member of the TNF receptor superfamily that was originally characterized based on its ability to suppress osteoclast formation [1, 2]. OPG binds to the receptor activator of NF-κB ligand (RANKL) and functions as a soluble decoy receptor for RANKL. In bone, OPG inhibits osteoclastogenesis by preventing RANKL from binding to its receptor RANK and, consequently promotes apoptosis of osteoclast . OPG is critical for osteoclastogenesis and, therefore, homeostasis of bone remodeling and bone mass . In addition to its role in bone metabolism, OPG has been implicated in mucosal immunity  and vascular systems. OPG is secreted by endothelial cells [5, 6] and promotes both proliferation and migration of microvascular endothelial cells [7, 8], and induces angiogenesis [8–10]. OPG can also serve as survival factor for endothelial cells [6, 8]. Furthermore, OPG acts as a decoy receptor of TNF-related apoptosis-inducing ligand (TRAIL) and neutralizes its function [11, 12]. TRAIL belongs to the TNF family of cytokines and has emerged as a promising anticancer agent because of its ability to selectively induce apoptosis in a broad host of tumor cells . TRAIL binding to its receptors (TRAIL-R1 and TRAIL-R2) initiates the extrinsic pathway of apoptosis, resulting in recruitment of the adapter protein Fas-associated death domain (FADD) and procaspase-8 in the death inducing signaling complex (DISC). Caspase-8 can directly activate the effector caspases (caspase‒3, ‒6, ‒7) leading to the execution of apoptosis . However, in ovarian cancer cells, the apoptotic signal must be further amplified by engaging the intrinsic (mitochondrial) pathway . In this context, caspase-8 cleaves Bid to generate an active tBid, which in turn activates proapoptotic Bax or Bak proteins, and induces mitochondrial outer membrane permeabilization (MOMP). The mitochondria then release proapoptotic factors that promote effector caspases activation.
Several reports have shown that OPG is a survival factor that can block TRAIL-induced apoptosis in tumor cells. Human prostate cancer cells were shown to secrete OPG at concentrations sufficient to inhibit TRAIL-induced apoptosis in vitro [16, 17]. Similarly, multiple myeloma cells were protected from TRAIL-induced apoptosis by OPG secreted from osteoblast-like cells and bone marrow stroma cells . OPG produced by breast cancer cells enhances tumor cell survival in vitro and in vivo by inhibiting TRAIL-induced apoptosis [19–22]. The production of OPG in colorectal cancer cells and the addition of exogenous OPG to colorectal cancer cells both caused resistance to TRAIL-induced apoptosis . Exogenous addition of OPG also mediates resistance to TRAIL-induced apoptosis in ovarian cancer cells .
Because OPG binds to TRAIL, OPG-mediated protection from TRAIL in various cancer cells has been assumed to be mainly related to its decoy function. However, the observations that OPG activates integrin/focal adhesion kinase (FAK)/ERK1/2 signaling in endothelial cells [7, 8] to promote proliferation and migration suggest that OPG regulates cell function directly. Indeed, it was suggested that OPG-mediated proliferation and migration of endothelial cells occurs in a TRAIL-independent manner [7, 25]. In ovarian cancer cells, activation of integrin/FAK and ERK1/2 signaling contribute to attenuate TRAIL-induced apoptosis [26, 27]. Based on these observations, we hypothesize that OPG might attenuate TRAIL-induced apoptosis in a TRAIL binding-independent manner by activating survival signaling pathways in ovarian cancer cells. The purpose of this study was to investigate whether exogenous OPG can confer protection against TRAIL-induced apoptosis independent from its ability to act as a TRAIL decoy receptor.
OPG attenuates TRAIL-induced apoptosis in a TRAIL binding-independent manner
OPG attenuates TRAIL-induced apoptosis through an integrin-dependent pathway
The engagement of integrin to its ligand triggers a signaling cascade that leads to the activation of FAK, one of the earliest even downstream in integrin signaling . Consistent with the role of integrin in OPG-mediated attenuation of TRAIL-induced apoptosis, we found that FAK was phosphorylated when OVCAR3 and CaOV3 cells were incubated with OPG while the levels of total FAK remained relatively stable (Figure 2B). We also observed a significant and stronger increase in the phosphorylation of FAK in primary OVC238A cells treated with OPG (Figure 2B). This could be related to the differential expression of integrins in ovarian cancer cell lines compared to primary ovarian cancer specimens . Nonetheless, these data suggest that both αvβ3 and αvβ5 integrin signaling, which results in FAK activation, are involved in OPG-mediated attenuation of TRAIL-induced apoptosis.
An Akt-dependent pathway mediates OPG-induced attenuation of TRAIL-induced apoptosis
OPG-mediated Akt activation is regulated by integrin/FAK signaling
Important aspects of ovarian cancer progression include resistance to drug-induced apoptosis. Early studies have shown that OPG, in paracrine or autocrine manners, functions as a survival factor for tumor cells by preventing apoptosis induced by TRAIL [16–23]. Indeed, soluble secreted OPG has been shown to act as a decoy receptor for TRAIL [11, 12]. In addition, OPG has been shown to promote angiogenesis and endothelial cell migration and proliferation by inducing integrin signaling [7–10]. Recent studies have also demonstrated that αvβ5 integrin/Fak signaling attenuates TRAIL-induced apoptosis in ovarian cancer cells by activating Akt survival pathway . These findings prompted us to investigate whether OPG can protect ovarian cancer cells in a TRAIL-binding independent manner. In the present study, we found that OPG attenuates TRAIL-induced apoptosis independently from its binding to TRAIL. Indeed, incubation of ovarian cancer cells with exogenous OPG, followed by removal of OPG and treatment with TRAIL significantly inhibited TRAIL-induced apoptosis (Figure 1), suggesting that OPG may attenuates TRAIL-induced apoptosis via TRAIL binding-dependent and -independent mechanisms.
Previous studies have shown that OPG rapidly activates integrin/FAK signaling in endothelial cells and that OPG-mediated integrin signaling is strongly inhibited by αvβ3 and αvβ5 integrin blocking antibodies [7, 8]. Similarly, we showed that OPG activates both αvβ3 and αvβ5 integrin signaling in ovarian cancer cells (Figure 2). These findings suggest that OPG-induced integrin/FAK signaling may be common in all OPG-responsive cell types. In addition, the fact that both OPG and malignant ascites activate integrin/FAK signaling and attenuate TRAIL-induced apoptosis suggest that integrin signaling is central to protect ovarian cancer cells from TRAIL cytotoxicity. Several recent studies have shown that Akt activation is important for ovarian cancer cell survival [15, 26, 31, 32]. In this study, we found that OPG-induced attenuation of TRAIL-induced apoptosis was significantly inhibited by chemical inhibitors of the PI3K/Akt pathway (Figure 3) and that OPG activates Akt in an integrin/FAK-dependent manner in ovarian cancer cells (Figure 4). Furthermore, although ERK1/2 was rapidly activated by OPG, experiments with ERK1/2 inhibitors showed that ERK1/2 activation was not required for OPG-induced attenuation of TRAIL-induced apoptosis (Figure 3).
Akt may be activated by various mechanisms, including growth factor receptors, cytokine receptors and G-protein coupled receptors . However, we found that αvβ3 and αvβ5 integrin blocking antibodies and siRNA-mediated downregulation of FAK almost completely abolish OPG-mediated Akt activation. Therefore, we conclude that integrin/FAK signaling is the main pathway involved in OPG-mediated Akt activation. This is consistent the recent study showing that inhibition of growth factor receptors and G-protein coupled receptors failed to block ascites-induced Akt activation in ovarian cancer cells . The inhibition of αvβ5 integrin/FAK signaling however resulted in the blockade of Akt activation in that study.
In conclusion, we have demonstrated that the αvβ3 and αvβ5 integrin/FAK/Akt pathway is involved in OPG-induced attenuation of TRAIL-induced apoptosis in ovarian cancer cells. Furthermore, the present study provides novel information about the mechanisms by which OPG attenuates TRAIL-induced apoptosis by demonstrating that OPG acts also in a TRAIL binding-independent manner.
Primary tumor cells and cell lines
The study was approved by the institutional review board of the Centre Hospitalier Universitaire de Sherbrooke. Written informed consent was obtained from the patient for the publication of this report and any accompaying images from women that undergone surgery by the gynecologic oncology service for OC. Primary tumor cells isolated from malignant ovarian cancer ascites were supplied by the Banque de tissus et de données of the Réseau de Recherche en Cancer of the Fonds de la Recherche du Québec en Santé (FRQS) affiliated with the Canadian Tumor Repository Network (CTRNet). Primary tumor cells (OVC238A) were isolated as follow: ovarian cancer ascites were centrifuged at 1000 rpm for 15 min and cells were washed twice with OSE medium (Wisent, St-Bruno, Québec, Canada). Cells were then resuspended in OSE medium supplemented with 10% FBS, β-estradiol (10-8 M), 2 mM glutamine, antibiotics and fungizone and plated into 75 cm2 flasks. All floating cells were removed the next day. Tumor cell samples were used at low passage (< 10). Primary tumor cells (OVC238A) were obtained from patients with advanced serous OC. These cells have been previously described and stained positive for epithelial tumor markers anti-CA125 and cytokeratine 8/18 and negative for fibroblast specific marker fibroblast antigen . The OC cell lines CaOV3 and OVCAR3 were obtained from American Type Culture Collection, (Manassas, VA) and maintained in a humidified 5% CO2 incubator at 37°C. Cells were passaged twice weekly. OVCAR3 cells were maintained in RPMI-1640 (Wisent, St-Bruno, QC, Canada) supplemented with 20% FBS, insulin (10 mg/L), glutamine (2 mM) and antibiotics. CaOV3 cells were cultured in DMEM/F12 (Wisent) supplemented with 10% FBS, 2 mM glutamine and antibiotics.
Recombinant human TRAIL was purchased from PeproTech (Rocky Hill, NJ). Recombinant OPG was purchased from R&D Systems (Mineapolis, MN). OPG ELISA was purchased from eBioscience (Vienna, Austria). Antibodies for Akt and FAK were from Cell Signaling. Antibodies for phospho-Akt (Ser-473) and phospho-FAK (Tyr-397) were form Life Technologies (Burlington, ON, Canada). ERK antibody was from Santa Cruz Biotech (Santa Cruz, CA). Integrin-blocking antibodies anti-αvβ3 (clone LM609) and anti- αvβ5 (clone PF16) were from Millipore (Temecula, CA). Anti-tubulin antibody was obtained from Sigma (Oakville, ON, Canada). Akt inhibitor 1/2 (1 L-6-hydroxymethyl-chiro-inositol 2(R)-2-O-methyl-3-O-octadecylcarbonate) was from Calbiochem (San Diego, CA). PI3K inhibitor LY294002 and MEK inhibitor U0126 was purchased from EMD (Billerica, MA).
Cell viability assays
For clonogenic survival assays, cells were plated into 25 cm2 tissue culture plates in standard medium. The next day, cells were incubated for 90 min in medium containing OPG (25 ng/ml). Cells were then extensively washed to remove any OPG and TRAIL (50 ng/ml) was added to fresh medium for 48 h. Cells were then washed with PBS and incubated in fresh medium into 6-well plates at the different densities for 14 days. Cells were fixed and stained with crystal violet. The number of colonies, consisting of > 50 cells, in triplicate was counted.
Once cells have reached confluence, the medium was removed and fresh medium was added. After 48 h, the conditioned medium was removed, centrifuged and stored at -20°C until used.
Cells were incubated in medium containing OPG (25 ng/ml) for 1 h. Cells were washed to remove OPG and TRAIL (50 ng/ml) was added to fresh medium for 24 h. The release of nucleosomal DNA into the cytoplasm as a measure of apoptosis was determined using the Cell Death Detection ELISA Kit (Roche, Laval, Québec, Canada) according to the manufacturer’s instruction. The absorbance was determined using a microplate reader at 410 nm.
The FAK and non-targeted (NT) siRNA oligonucleotides were purchased from Dharmacon Research Inc (Ottawa, ON, Canada). Cells were seeded in six-well plates and allowed to adhere for 24 h. Cells (50% confluent) were transfected with a mixture containing Lipofectamine 2000 (Life Technology), OPTIMEM (Life Technology) and siRNA. The siRNA/Lipofectamine complex was then added to the medium. The final concentration of siRNA was 10 mM. Cells were incubated for 4–6 h at 37°C and fresh medium was then added.
Experiments were performed in triplicate, and data presented as mean ± SD. Student’s paired t-test was used to analyze differences between the treatment conditions and their controls. The threshold for statistical significance is P < 0.05.
This work was supported by funds from the Canadian Institutes of Health Research (MOP -115072) (A.P.). We wish to thank the Banque de tissus et de données du Réseau de Recherche en Cancer des Fonds de la Recherche du Québec en Santé (FRQS), affiliated to the Canadian Tumor Repository Network (CTRNet) for providing the primary tumor samples.
- Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ: Osteoprotegerin: a novel secreted protein involved in the regulation bone density. Cell 1997, 89: 309–319.PubMedView ArticleGoogle Scholar
- Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K: Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998, 139: 1329–1337.PubMedGoogle Scholar
- Dougall WC: Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clin Cancer Res 2012, 18: 326–335.PubMedView ArticleGoogle Scholar
- Vidal K, Serrant P, Schlosser B, van der Broek P, Lorget F, Donnet-Hughes A: Osteoprotegerin production by human intestinal cells: a potential regulator of mucosal immune responses. Am J Physiol Gastrointes Liver Physiol 2004, 287: G836-G844.View ArticleGoogle Scholar
- Reid PE, Brown NJ, Holen I: Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact. Mol Cancer 2009, 8: 49.PubMed CentralPubMedView ArticleGoogle Scholar
- Malyankart UM, Scatena M, Suchland KL, Yun TJ, Clark EA, Giachelli CM: Osteoprotegerin is an αvβ3-induced, NF-κB-dependent survival factor for endothelial cells. J Biol Chem 2000, 275: 20959–20962.View ArticleGoogle Scholar
- Kobayashi-Sakamoto M, Isogai E, Hirose K, Chiba I: Role of αv integrin in osteoprotegerin-induced endothelial cell migration and proliferation. Microvasc Res 2008, 76: 139–144.PubMedView ArticleGoogle Scholar
- Kobayashi-Sakamoto M, Isogai E, Holen I: Osteoprotegerin induces cytoskeletal reorganization and activates FAK, Src, and ERK signaling in endothelial cells. Eur J Haematol 2010, 85: 26–35.PubMedGoogle Scholar
- McGonigle JS, Giachelli CM, Scatena M: Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function. Angiogenesis 2009, 12: 35–46.PubMedView ArticleGoogle Scholar
- Benslimane-Ahmim Z, Poirier F, Delomenie C, Lokajczyk A, Grelact F, Galy-Fauroux I, Mohamedi A, Fischer AM, Heymann D, Lutomski D, Boisson-Vidal C: Mechanistic study of the proangiogenic effect of osteoprotegerin. Angiogenesis 2013, 16: 575–593.PubMedView ArticleGoogle Scholar
- Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR: Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998, 273: 14363–14367.PubMedView ArticleGoogle Scholar
- Truneh A, Sharma S, Silverman C, Khandekar S, Reddy MP, Deen KC, McLaughlin MM, Srinivasula SM, Livi GP, Marshall LA, Alnemri ES, Williams WV, Doyle ML: Temperature-sensitive differential affinity of TRAIL for its receptors. J Biol Chem 2000, 275: 23319–23325.PubMedView ArticleGoogle Scholar
- Abdulghani J, El‒Deiry WS: TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets 2010, 14: 1091–1108.PubMedView ArticleGoogle Scholar
- Goncharenko-Khaider N, Lane D, Matte I, Rancourt C, Piché A: Targeted ovarian cancer treatment: the TRAILs of resistance. Am J Cancer Res 2012, 2: 75–92.Google Scholar
- Goncharenko-Khaider N, Lane D, Matte I, Rancourt C, Piché A: The inhibition of Bid expression by Akt leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells. Oncogene 2010, 29: 5523–5536.PubMed CentralPubMedView ArticleGoogle Scholar
- Holen I, Croucher PI, Hamdy FC, Eaton CL: Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 2002, 62: 1619–1623.PubMedGoogle Scholar
- Corey E, Brown LG, Kiefer JA, Quinn JE, Pitts TE, Blair JM, Vessella RL: Osteoprotegerin in prostate cancer bone metastasis. Cancer Res 2005, 65: 1710–1718.PubMedView ArticleGoogle Scholar
- Shipman CM, Croucher PI: Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 2003, 63: 912–916.PubMedGoogle Scholar
- Neville-Webbe HL, Cross NA, Eaton CL, Nyambo R, Evans CA, Coleman RE, Holen I: Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat 2004, 86: 269–279.PubMedView ArticleGoogle Scholar
- Holen I, Cross SS, Neville-Webbe HL, Cross NA, Balasubramanian SP, Croucher PI, Evans CA, Lippitt JM, Coleman RE, Eaton CL: Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo – a role in tumour cell survival? Breast Cancer Res Treat 2005, 92: 207–215.PubMedView ArticleGoogle Scholar
- Fisher JL, Thomas-Mudge RJ, Elliott J, Hards DK, Sims NA, Slavin J, Martin TJ, Gillespie MT: Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res 2006, 66: 3620–3628.PubMedView ArticleGoogle Scholar
- Rachner TD, Benad P, Rauner M, Goettsch C, Singh SK, Schoppet M, Hofbauer LC: Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis. J Cell Biochem 2009, 108: 106–116.PubMedView ArticleGoogle Scholar
- De Toni EN, Thieme SE, Herbst A, Behrens A, Stieber P, Jung A, Blum H, Göke B, Kolligs FT: OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer. Clin Cancer Res 2008, 14: 4713–4718.PubMedView ArticleGoogle Scholar
- Lane D, Matte I, Rancourt C, Piché A: Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis. J Ovarian Res 2012, 5: 34.PubMed CentralPubMedView ArticleGoogle Scholar
- Cross SS, Yang Z, Brown NJ, Balasubramanian SP, Evans CA, Woodward JK, Neville-Webbe HL, Lippitt JM, Reed MW, Coleman RE, Holen I: Osteoprotegerin (OPG)-a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int J Cancer 2006, 118: 1901–1908.PubMedView ArticleGoogle Scholar
- Lane D, Goncharenko-Khaider N, Rancourt C, Piché A: Ovarian cancer ascites protects from TRAIL-induced cell death through αvβ5 integrin-mediated focal adhesion kinase and Akt activation. Oncogene 2010, 29: 3519–3531.PubMedView ArticleGoogle Scholar
- Goncharenko-Khaider N, Matte I, Lane D, Rancourt C, Piché A: Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis. Mol Cancer 2012, 11: 84.PubMed CentralPubMedView ArticleGoogle Scholar
- Lane D, Cartier A, L’Espérance S, Côté M, Rancourt C, Piché A: Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in human ovarian carcinoma cells. Gynecol Oncol 2004, 93: 594–604.PubMedView ArticleGoogle Scholar
- Stupack DG, Cheresh DA: Get a ligand, get a life: integrins, signalling and cell survival. J Cell Science 2002, 115: 3729–3734.PubMedView ArticleGoogle Scholar
- Cannistra SA, Ottensmeier C, Niloff J, Orta B, DiCarlo J: Expression and function of β1 and αvβ3 integrins in ovarian cancer. Gynecol Oncol 1995, 58: 216–225.PubMedView ArticleGoogle Scholar
- Lane D, Robert V, Grondin R, Rancourt C, Piché A: Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian cancer cells. Int J Cancer 2007, 121: 1227–1237.PubMedView ArticleGoogle Scholar
- Mao Y, Xu J, Song G, Zhang N, Yin H: Twist2 promotes ovarian cancer cell survival through activation of Akt. Oncol Lett 2013, 6: 169–174.PubMed CentralPubMedGoogle Scholar
- Dobbin ZC, Landen CN: The importance of the PI3K/AKT/mTOR pathway in the progression of ovarian cancer. Int J Mol Sci 2013, 14: 8213–8227.PubMed CentralPubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.